AngioDynamics (ANGO) AI Stock Analysis

• Market Cap: $464.11M
• Dividend Yield: N/A
• Average Volume (3M): 745.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.09
• Revenue Growth: 2.73%
• EPS Growth: 87.03%
• Country: US
• Employees: 748
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.00
• Shares Outstanding: 41,217,384
• 10 Day Avg. Volume: 465,473
• 30 Day Avg. Volume: 745,029
• PEG Ratio: 0.15
• Price to Book (P/B): 2.28
• Price to Sales (P/S): 1.43
• P/FCF Ratio: -28.65
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: 1.36
• Enterprise Value/Gross Profit: 2.53
• Enterprise Value/Ebitda: -123.44
• 1Y Price Target: $19.33
• Price Target Upside: 77.01% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -0.33
• Revenue Forecast (FY): $310.26M

• Rating: 51 Neutral
• Price Target: $11.50 ▲(5.31% Upside)

The score is held back primarily by weak financial performance (ongoing losses and negative TTM cash flow) and bearish technicals (below major moving averages with negative MACD). These are partly offset by constructive earnings-call signals, including raised FY2026 revenue and adjusted EBITDA guidance and expectations for full-year cash-flow positivity, while valuation support is limited due to negative earnings and no dividend yield data.

Positive Factors

Strong balance sheet

Very low leverage and sizable equity give AngioDynamics durable financial flexibility to fund R&D, manufacturing transitions, and commercialization without immediate refinancing. This lowers default risk, supports opportunistic M&A or capital spending, and helps absorb short-term cash burn while executing growth initiatives.

Revenue mix shift to higher-margin Med Tech

A sustained shift toward Med Tech, which grew faster and contributes higher margins, improves structural revenue quality. Higher-margin product mix supports durable gross margin expansion and recurring consumable sales, making future profitability less reliant on one-time capital equipment transactions.

Regulatory and product momentum

New CPT reimbursement and accelerating product adoption create lasting demand tailwinds for NanoKnife probes and procedures. Regulatory clearances and IDE approvals for thrombectomy and AngioVac studies expand addressable markets and clinical adoption, supporting sustained procedure volume growth and recurring consumable revenue.

Negative Factors

Negative operating cash flow

Persistent negative operating cash flow constrains internal financing for commercialization and R&D. Even with cash on hand, continued cash burn forces reliance on reserves or external funding if losses persist, limiting the company's ability to scale investments without diluting shareholders or increasing leverage.

Ongoing net losses

Continued net losses and negative operating profit mean profitability is not yet established. This reduces free cash flow conversion and constrains reinvestment capacity; sustained improvement is required to convert operational momentum into durable earnings and to justify reduced dependency on cost cuts or one-time items.

Execution & cost pressures (tariffs, H2 investments, one-offs)

Structural headwinds like tariff exposure and manufacturing transition underabsorption increase unit costs. Planned second-half investments intentionally depress EBITDA, and reliance on one-time transactional gains makes recent margin gains less certain. These execution risks could delay durable margin recovery.

AngioDynamics Business Overview & Revenue Model

Company Description

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

How the Company Makes Money

AngioDynamics generates revenue through multiple key streams primarily centered around the sale of its medical device products. The company's main revenue sources include vascular access products, which provide healthcare professionals with the tools necessary for catheter placement and administration of medications; ablation systems used for the treatment of tumors and other conditions; and drainage systems designed for effective fluid management. Furthermore, AngioDynamics benefits from recurring revenue through the sale of consumable supplies and accessories that accompany its devices. The company also engages in partnerships with healthcare providers and distributors to enhance market reach and customer access, thereby contributing to its earnings. Additionally, AngioDynamics may explore collaborations with other medical technology firms to expand its product offerings and entry into new markets, further enhancing its revenue potential.

AngioDynamics Financial Statement Overview

Summary

Balance sheet is strong with effectively zero debt and sizable equity (Score 78), but operations remain challenged with negative TTM operating profit/net income (Income Statement Score 32) and negative TTM operating cash flow and free cash flow (Cash Flow Score 30). Revenue stabilization and improved losses versus FY2024 are positives, but sustained profitability and cash generation are not yet established.

Income Statement

TTM (Trailing-Twelve-Months) revenue is modestly higher (about +2.2%), showing stabilization after prior annual declines. Gross margin remains healthy and steady (roughly 51%–54% across periods), but profitability is still weak: TTM operating profit and net income are negative, with net margin around -10.7%. Losses have improved materially versus FY2024 (which showed an unusually large net loss), but results remain meaningfully unprofitable and earnings quality is not yet where it needs to be for a higher score.

Balance Sheet

The balance sheet is a clear strength: TTM total debt is effectively zero, and annual periods also show very low leverage (debt-to-equity generally near 0.02 in recent years, with a higher—still moderate—level in FY2023). Equity remains positive and sizable relative to assets, providing financial flexibility. The key weakness is returns: return on equity is negative across all periods due to ongoing net losses, which limits the overall balance sheet score despite very conservative leverage.

Cash Flow

Cash generation is currently pressured: TTM operating cash flow and free cash flow are both negative, and TTM free cash flow declined versus the prior period. While the company has shown it can generate cash in the past (FY2021 posted positive operating and free cash flow), more recent years have swung back to cash burn (negative operating and free cash flow in FY2022, FY2024, FY2025 and TTM). The main positive is that free cash flow has generally been better than net income (losses include non-cash items), but sustained negative operating cash flow keeps the score low.

Breakdown	TTM	May 2025	May 2024	May 2023	May 2022	May 2021
Income Statement
Total Revenue	307.31M	292.50M	303.91M	338.75M	316.22M	291.01M
Gross Profit	165.07M	157.71M	154.70M	174.25M	165.73M	156.79M
EBITDA	-3.38M	1.74M	-6.13M	12.19M	11.13M	-9.28M
Net Income	-27.71M	-33.99M	-184.35M	-52.44M	-26.55M	-31.55M
Balance Sheet
Total Assets	269.68M	280.14M	317.67M	532.64M	552.75M	561.44M
Cash, Cash Equivalents and Short-Term Investments	41.64M	55.89M	76.06M	44.62M	28.82M	48.16M
Total Debt	0.00	0.00	4.73M	64.58M	33.78M	20.00M
Total Liabilities	93.35M	97.17M	112.08M	154.34M	128.26M	121.98M
Stockholders Equity	176.33M	182.97M	205.59M	378.30M	424.49M	439.46M
Cash Flow
Free Cash Flow	-9.33M	-14.59M	-33.93M	-4.27M	-11.49M	18.91M
Operating Cash Flow	-5.60M	-10.13M	-28.16M	78.00K	-7.19M	24.09M
Investing Cash Flow	-8.98M	-10.18M	123.72M	-9.75M	-19.31M	-13.71M
Financing Cash Flow	1.43M	-255.00K	-64.25M	25.42M	7.68M	-16.99M

AngioDynamics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.92
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANGO, the sentiment is Positive. The current price of 10.92 is above the 20-day moving average (MA) of 10.61, below the 50-day MA of 11.62, and above the 200-day MA of 10.74, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 52.82 is Neutral, neither overbought nor oversold. The STOCH value of 63.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANGO.

AngioDynamics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTMD	71 Outperform	$209.39M	18.76	9.59%	2.15%	-12.35%	-17.20%
INFU	68 Neutral	$154.55M	29.63	9.95%	―	6.23%	283.88%
STXS	62 Neutral	$194.12M	-7.22	-170.24%	―	19.61%	-3.42%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANGO	51 Neutral	$464.11M	-16.53	-15.26%	―	2.73%	87.03%
OSUR	47 Neutral	$197.27M	-3.51	-15.30%	―	-43.95%	-620.21%
SMTI	42 Neutral	$170.58M	-4.52	-27.19%	―	30.55%	-340.19%

AngioDynamics Corporate Events

AngioDynamics announces CEO transition and leadership retention plan

On February 3, 2026, AngioDynamics entered into a Transition and Retirement Agreement with President and CEO James C. Clemmer, confirming that he will remain in his role until a successor is appointed or until November 30, 2026, with the potential for month‑to‑month extensions. The agreement provides for continued vesting of Clemmer’s existing equity awards through his ultimate separation from service, after which his stock options and service-based restricted stock units will fully vest and his performance-based restricted stock units will remain eligible to vest according to their terms. In connection with this leadership transition, on January 30, 2026, the board approved retention agreements for the executive leadership team, granting cash retention awards tied to continued employment through six months after the new CEO’s start date or June 1, 2027, with key named executives eligible for awards equal to 150% of base salary and other leaders eligible for awards equal to 50% of base salary, underscoring the board’s focus on ensuring management stability during the CEO succession process.

The most recent analyst rating on (ANGO) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on AngioDynamics stock, see the ANGO Stock Forecast page.

AngioDynamics Highlights Growth Strategy at J.P. Morgan Conference

On January 14, 2026, President and CEO James Clemmer presented AngioDynamics’ growth strategy and product portfolio at the J.P. Morgan 44th Annual Healthcare Conference, highlighting the company’s transition since 2020 into a more growth-focused MedTech business with a higher-margin mix, improved operations, and a robust pipeline in cardiovascular and prostate care. The presentation underscored the company’s positioning in large and underpenetrated U.S. markets—such as peripheral artery disease, venous thromboembolism and prostate care—citing strong adoption of its Auryon peripheral artery disease platform, expanding reimbursement, and FDA-cleared AlphaVac mechanical thrombectomy system for pulmonary embolism following the APEX-AV pivotal study, which showed a significantly greater reduction in clot burden than competing technologies, reinforcing AngioDynamics’ bid for sustained profitable growth and a stronger competitive standing in interventional cardiovascular care.

The most recent analyst rating on (ANGO) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on AngioDynamics stock, see the ANGO Stock Forecast page.

AngioDynamics posts strong Q2 results, raises 2026 outlook

On January 6, 2026, AngioDynamics reported financial results for its fiscal second quarter ended November 30, 2025, highlighted by 8.8% year-on-year pro forma net sales growth to $79.4 million and the fifth consecutive quarter of double-digit growth in its Med Tech segment, which rose 13.0% to $35.7 million. Segment performance was driven by strong gains in Auryon, Mechanical Thrombectomy, and NanoKnife, contributing to an improved gross margin of 56.4%, a sharply reduced adjusted net loss of $0.1 million, and higher adjusted EBITDA of $5.9 million, while the company generated $4.7 million in cash, ended the quarter with $41.6 million in cash and no debt, and raised full-year fiscal 2026 guidance for net sales and adjusted EBITDA. Operationally, the quarter brought notable regulatory and strategic milestones, including FDA IDE approvals for the APEX-Return study of the AlphaReturn Blood Management System with AlphaVac in acute pulmonary embolism and for the PAVE study of AngioVac in right-sided infective endocarditis, as well as FDA 510(k) clearance expanding indications for the modified AlphaVac F1885 System, the successful conclusion of remaining patent litigation items with Bard, and the announcement that President and CEO Jim Clemmer will retire during fiscal 2027 as the board launches a search for his successor, developments that collectively strengthen the company’s mechanical thrombectomy franchise and underscore a pivotal leadership transition.

The most recent analyst rating on (ANGO) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on AngioDynamics stock, see the ANGO Stock Forecast page.